Xspray Pharma AB (publ) XSPRAY
Updated: 12 Jun 2026
No signal published yet
We already track Xspray Pharma and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Xspray Pharma AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Xspray Pharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 4, 2026, the company announced that the U.S. FDA issued a Complete Response Letter (CRL) regarding the application for Nilopki, meaning it will not be approved in its current form. The FDA requested additional data concerning manufacturing scale-up and dosage equivalence, making a 2026 launch unlikely. The company intends to address these issues for a future resubmission of the application.
What Firelda Watch includes for Xspray Pharma AB (publ)
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Xspray Pharma AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Xspray Pharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more